Merck Targeted Therapy Extends Survival by Seven Months in Advanced Endometrial Cancer

A new targeted therapy has extended the lives of women with advanced endometrial cancer by nearly seven months, marking a major breakthrough for a disease with historically dismal outcomes. The treatment fundamentally alters the prognosis for patients who have exhausted standard options.[8]

The phase 3 TroFuse-005 trial results, presented at the 2026 European Society for Medical Oncology (ESMO) Congress, showed that the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) reduced the risk of death by 32 percent. The drug was compared directly against standard chemotherapy regimens.[1][3]

For patients whose cancer has progressed after initial chemotherapy and immunotherapy, no standard life-prolonging treatments previously existed. The international trial enrolled 776 participants across 29 countries to test whether this targeted biological approach could outperform traditional cytotoxic drugs.[4][8]

The trial specifically targeted a notoriously difficult-to-treat demographic. All enrolled women had previously received platinum-based chemotherapy and anti-PD-1 or PD-L1 immunotherapy, leaving them with highly resistant disease and very few remaining medical interventions.[4][6]

"These positive results from the first phase 3 trial using sacituzumab tirumotecan after immunotherapy establishes this drug as a new standard treatment in recurrent endometrial cancer," said Dr. Bhavana Pothuri. She serves as a principal investigator at NYU Langone Health.[2][8]

Targeting the TROP2 Protein

The drug operates as an antibody-drug conjugate, a class of therapies often described as biological guided missiles. Sac-TMT specifically hunts for TROP2, a protein that sits in heavy abundance on the surface of endometrial cancer cells.[2][8]

Once the antibody binds to the TROP2 receptor, it is internalized by the tumor. It then releases a potent topoisomerase I inhibitor payload directly inside the cancer cell, destroying the malignancy while largely sparing surrounding healthy tissue.[7][8]

Merck, which is developing the drug in partnership with China-based Kelun-Biotech, designed sac-TMT with a unique bifunctional linker. This engineering choice maximizes the delivery of the toxic payload into the tumor while preventing the chemical from leaking into the bloodstream prematurely.[5][6]

The clinical data revealed a stark divergence in patient trajectories over the 14-month follow-up period. Participants receiving sac-TMT lived a median of 19.0 months, compared to just 12.1 months for those assigned to the chemotherapy control group.[1][4]

Disease progression was similarly stalled by the experimental infusion. The targeted therapy extended median progression-free survival to 7.2 months, nearly doubling the 3.9 months observed in patients receiving standard doxorubicin or paclitaxel regimens.[3][6]

Tumor Shrinkage and Response Rates

Beyond extending overall survival, the drug proved highly effective at actively shrinking existing tumors. The objective response rate reached 35.1 percent for the sac-TMT cohort, more than twice the 17.3 percent rate seen with conventional chemotherapy.[1][3]

Complete responses, where tumors entirely disappear from radiological imaging, were recorded in 6.1 percent of patients on the experimental drug. Furthermore, these therapeutic responses proved highly durable, lasting a median of 11.1 months compared to 6.9 months for chemotherapy.[3][7]

"The curves separate early and remain separated over time, suggesting consistent benefit," noted Dr. Domenica Lorusso during her presentation to the oncology congress. She serves as the global lead investigator from Humanitas University in Milan.[7]

The robust efficacy data has already prompted rapid regulatory momentum. The United States Food and Drug Administration has accepted Merck's application for approval, setting a target action date of June 15, 2027, and granting the drug priority review status.[5]

Merck also earned an FDA Commissioner's National Priority Voucher for the therapy, which is expected to further accelerate the agency's review process. The company is positioning the drug as a cornerstone of its post-Keytruda oncology strategy.[5]

Managing the Toxicity Profile

While the targeted mechanism spares many healthy cells, the treatment still carries a substantial side-effect profile. Nearly 97 percent of patients treated with sac-TMT experienced some form of treatment-related adverse event during the clinical trial.[6]

Severe adverse events, classified as grade 3 or higher, occurred in 54.4 percent of the sac-TMT group, compared to 41.4 percent in the chemotherapy cohort. The most common severe complications included anemia and neutropenia, a dangerous drop in infection-fighting white blood cells.[6]

Patients also frequently reported oral mucositis, which causes painful inflammation in the mouth, alongside dry or itchy eyes. Despite these elevated toxicity rates, treatment discontinuation remained low, suggesting the complications were clinically manageable for most participants.[4][8]

Dr. Pothuri emphasized that compared to other TROP2-directed therapies she has administered, sac-TMT was notably better tolerated by patients. This tolerability allowed participants to maintain their overall quality of life while receiving the intravenous infusions every two weeks.[4][6]

Addressing a Growing Crisis

The breakthrough arrives at a critical moment for gynecological oncology. Endometrial cancer is the most common malignancy of the female reproductive system, and both its incidence and mortality rates have been climbing steadily over the past decade.[2][8]

In the United States alone, an estimated 68,000 new cases and 14,000 deaths are projected for 2026. The rising death toll is largely driven by highly aggressive subtypes of the disease, which disproportionately affect Black patients.[8]

For women whose cancer has spread to distant organs, survival rates have historically remained bleak. The introduction of a highly effective post-immunotherapy option fundamentally alters the long-term outlook for this vulnerable patient population.[2][8]

Researchers are now looking beyond the current clinical indication. The success of the TroFuse-005 trial suggests that sac-TMT could eventually be deployed against other TROP2-expressing malignancies, including certain lung, breast, and intestinal cancers.[2][8]